The clinical benefit of continuous glucose monitoring (CGM) in non-insulin-treated type 2 diabetes (T2D) and those with earlier stages of glucose dysregulation is controversial and relatively unstudied.

In the largest study to date on the above population, we showed that in 665 individuals with non-insulin-treated T2D, prediabetes, or no history of diabetes, 10-day use of the Freestyle Libre CGM and the Sugar AI mobile app that integrates CGM data with food logging/physical activity and provides continuous feedback to users, TIR improved significantly in both T2D and those without diabetes. Among those with low baseline TIR, improvement was 22.7% and 23.2%, respectively, for T2D and nondiabetic individuals.

Individuals without a prior diagnosis of T2D and lower body mass index (BMI) showed the greatest response to the intervention.

Results from this study indicate that short-term use of CGM along with exposure to activity and food insights can significantly improve TIR in participants with non-insulin-treated T2D and earlier stages of glucose dysregulation.